A multicenter, double-blind, placebo-controlled, parallel-group study of ONO-5163 in patients with secondary hyperparathyroidism on hemodialysis

Trial Profile

A multicenter, double-blind, placebo-controlled, parallel-group study of ONO-5163 in patients with secondary hyperparathyroidism on hemodialysis

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2017

At a glance

  • Drugs Etelcalcetide (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 05 Jan 2017 Results published in the Nephrology Dialysis Transplantation
    • 30 May 2016 New trial record
    • 24 May 2016 According to an Ono Pharmaceuticals media release, results from this study were presented at the 53rd European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top